Patient was a 36-year-old Brazilian male physician of Japanese descent with no comorbidities or atypical signs. Six years previously he presented intermittent erythematous papules on the trunk and face, in addition to pruritus aggravated by heat or alcohol intake. Six months previously he evolved with erythroderma, treated with cyclosporine (3mg/kg/d), hydration, and topical corticosteroids, with partial improvement. On physical examination: erythroderma, facial infiltration, and infiltrated erythematous plaques (mainly cubital and popliteal), xeroderma, thickening of the greater
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DISCUSSION
Hypereosinophilic syndrome (HES) is characterized by persistently elevated peripheral eosinophil count (> 1,500/µL) associated with symptomatic organ involvement, excluding secondary causes of eosinophilia (Chart 1). 1 
It is classified as myeloproliferative (HES-M), secondary or reactive (HES-L), and idiopathic (HES-I) (Chart 2)
.2 HES is a rare disease (5,000 cases/year in the United States of America), potentially fatal, and the organs most frequently involved are skin, lungs, intestine, heart, kidneys, eyes, and peripheral nervous system. The most serious complication is cardiac, which should be investigated in all cases. In adults, the syndrome is more common in males (ratio 9:1), and mean age at onset is 50 years. Investigation of organ involvement and sub-classification are decisive for treatment and prognosis. Peripheral eosinophilia should be confirmed, but its persistence for more than six months is no longer mandatory
In symptomatic patients with confirmed eosinophilia and organ involvement, proceed to treatment to prevent organ damage; any duration is significant, even less than six months
Symptomatic organ involvement secondary to hypereosinophilia
Signs and/or symptoms of organ involvement are not mandatory
At the time of diagnosis, it is very difficult to predict evolution in asymptomatic patients. Some may be asymptomatic at first evaluation and either remain asymptomatic or evolve due to tissue damage or organ involvement Adequate control with systemic corticosteroids alone or in combination with hydroxyurea, mepolizumab, or tocilizumab Chronic recurrent.
Occasional development of lymphoma
A B
Cutaneous manifestations of HES require differential diagnosis with urticaria, pruritus sine materia, mycosis fungoides, cutaneous adverse drug reactions, contact dermatitis, and atopic dermatitis. Dermatologists should be alert to pruritic erythematous papules, urticaria, angioedema, dermographism, oral and genital ulcers, centrifugal annular erythema, acral bullae, and erythroderma. Histopathologic examination of the skin lesion is usually nonspecific, with viable eosinophilic infiltration. [4] [5] [6] [7] In an endemic country like Brazil, a presentation with polyneuropathy requires ruling out leprosy, which is unlikely in this case because of the pruritus and histology.
In this case, treatment began with prednisone 1mg/kg/day, with important improvement in the skin lesions, eosinophilia (580/ µL), and pruritus after 30 days. Bone marrow biopsy did not show neoplastic infiltration, FISH cytogenetic test did not reveal deletion or translocation of the FIP1L1 and PDGFRA genes, JAK2 mutation was negative, and immunophenotyping did not show clonal lymphocyte populations. Adjuvant therapy with hydroxyurea was scheduled in conjunction with the Department of Hematology.
The case was classified as HES-I based on the absence of lymphocytic phenotypical abnormalities or genetic alterations.
Presence of peripheral neuropathy, absence of atopic signs, and worsening of the clinical picture with alcohol intake were characteristic. High IgE levels, good response to corticosteroid therapy, and low serum tryptase level and eosinophil count < 100,000/µL are associated with better prognosis. Therapeutic success in HES-I has been reported with tofacitinib and mepolizumab. 4, [8] [9] [10] Diagnosis of HES is often delayed due to its pleomorphic dermatological manifestations and insidious evolution. It is thus crucial that in all cases of erythroderma, HES should be considered as a differential diagnosis. 6,7 q
